TORONTO, ONTARIO–(Marketwired – April 18, 2017) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) announces the Company’s board has granted a total of 2,100,000 stock options to its directors, officers and certain scientists pursuant to the Company’s stock option plan and the requirements of the TSX Venture Exchange (TSXV).
Press Releases
Arch Biopartners’ Lead Anti-Bacterial Drug Candidate AB569 to Enter Investigator-Sponsored Phase I Human Trial
TORONTO, ONTARIO–(Marketwired – April 13, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced that the Cincinnati Veterans Affairs Medical Center (CVAMC) will conduct an investigator initiated Phase I human trial to evaluate the safety and pharmacokinetic profile of AB569, the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs.
Arch Biopartners Closes Non-Brokered Private Placement Financing
TORONTO, ONTARIO–(Marketwired – Feb. 28, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:FOIFF) a portfolio based biotechnology company, announced today it has raised $400,000 with the closing of the non-brokered private placement the Company announced in a press release February 21, 2017 (The “Offering”).
Arch Biopartners Announces TSXV Stock Ticker Symbol Change to “ARCH”
TORONTO, ONTARIO–(Marketwired – Feb. 23, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, announced today that the Company’s common shares will begin trading under the new stock ticker symbol “ARCH” on the TSX Venture Exchange (TSXV), effective at the open of trading on February 24, 2017.
Arch Biopartners Announces Non-Brokered Private Placement Financing
TORONTO, ONTARIO–(Marketwired – Feb. 21, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 1,000,000 common shares priced at $0.40 per common share (the “Common Shares”) for gross proceeds of up to $400,000 (the “Offering”).
Arch Biopartners Appoints Patrick Vink to Board of Directors
TORONTO, CANADA–(Marketwired – Dec. 12, 2016) – Arch Biopartners, Inc., (TSX VENTURE:ACH) (OTCBB:FOIFF) (Arch or the Company) is pleased to announce that Dr. Patrick Vink has joined its Board of Directors effective December 12th, 2016.
Arch Biopartners Collaborates With Team at Cincinnati Veterans Affairs Medical Center to Prepare Phase I and II Human Trial Protocol and Application for AB569
TORONTO, ONTARIO–(Marketwired – Oct. 27, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced it has agreed to sponsor Dr. Ralph Panos and his clinical trial team at the Cincinnati Veterans Affairs Medical Center (CVAMC) to prepare a phase I and phase II human trial protocol and an application to conduct investigator initiated trials evaluating the safety and efficacy of AB569.
Arch Biopartners Announces Issuance of U.S. Patent for Metablok
TORONTO, CANADA–(Marketwired – Oct. 11, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH) (OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 9,464,114 titled, “Peptides that Block Leukocyte Recruitment and Methods of Use”.
Arch Biopartners Engages Catalent to Begin Manufacturing Process for AB569
TORONTO, ONTARIO–(Marketwired – Aug. 10, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced it has engaged Catalent Inhalation, a division of Catalent Pharma Solutions (Catalent), to begin the manufacturing process for its drug AB569 in preparation for the first human trials involving patients with antibiotic resistant lung infections.
Arch Biopartners Forms Clinical and Medical Advisory Board for AB569
TORONTO, ONTARIO–(Marketwired – July 18, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced the formation of a clinical and medical advisory board for AB569, the Company’s bactericidal drug for treating antibiotic resistant infections in lungs and the urinary tract.